Apellis And Sobi Say Phase 2 MERIDIAN Study In ALS Did Not Meet Primary Endpoint; Say Based On Lack Of Efficacy, Companies Plan To Discontinue Development Of Systemic Pegcetacoplan For ALS
Portfolio Pulse from Benzinga Newsdesk
Apellis Pharmaceuticals and Sobi announced that their Phase 2 MERIDIAN study in ALS did not meet its primary endpoint. Due to the lack of efficacy, the companies plan to discontinue the development of systemic pegcetacoplan for ALS.
May 25, 2023 | 11:06 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Apellis Pharmaceuticals' stock may be negatively impacted by the failure of the Phase 2 MERIDIAN study in ALS and the discontinuation of systemic pegcetacoplan development for ALS.
The failure of the Phase 2 MERIDIAN study in ALS and the discontinuation of systemic pegcetacoplan development for ALS represent a setback for Apellis Pharmaceuticals. This negative news may lead to a decrease in investor confidence and a potential drop in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100